Can a diabetes drug boost weight loss after bypass surgery?
NCT ID NCT06162715
First seen Jun 27, 2026 · Last updated Aug 05, 2026 · Updated 2 times
Summary
This pilot trial tests whether tirzepatide, a drug used for diabetes and weight loss, can help people who still have obesity one year after gastric bypass surgery. Thirty participants will either receive the drug or standard care. The study tracks weight changes and any stomach-related side effects.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Tirzepatide (also known as Zepbound or Mounjaro)
- What this could lead to
- If it works, this could offer a new option for people who still have obesity after gastric bypass surgery, helping them lose more weight.
- What could go wrong
- This is a small pilot study with only 30 people, so results may not apply to everyone. Side effects like gastrointestinal symptoms are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2/3
Runs two stages together: whether the treatment works, then large-scale confirmation.
- Participants
-
About 30 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Oct 2024
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
25 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Subject must be able to understand and provide informed consent. 2. BMI \> 30 12 months after bariatric surgery. 3. Age \> 25 and \< 65 4. Patients undergoing primary Roux-en-Y Gastric Bypass Exclusion Criteria: 1. Inability or unwillingness of a subject to give written informed consent or comply with the study protocol. 2. Diagnosis of type I Diabetes 3. Revisional bariatric surgery (prior adjustable gastric band, sleeve gastric, vertical banded gastroplasty). 4. Use of medications for type 2 di 5. Hemoglobin A1c \> 8.5 in last 3 months. 6. Patient-reported Tobacco, e-cigarette, or smoked marijuana use within 12 months As this would preclude patients from undergoing bariatric surgery. 7. Personal history of pancreatitis as determined by history. 8. Personal or family history of medullary thyroid cancer by history or multiple endocrine neoplasia syndrome type 2 9. Pregnancy by urine testing, current lactation, or plans to become pregnant during the study period. 10. Use of systemic glucocorticoids in the past 28 days 11. Myocardial infarction, unstable angina, stroke, or heart failure (NYHA class II) within 1 year by history. 12. History of solid organ transplant. 13. History of physician-diagnosed malignancy (other than excised non-melanoma skin cancer) in the past 5 years. 14. Current uncontrolled hypertension (systolic \>150, diastolic \>90) or untreated hyperthyroidism. 15. Current, diagnosed, or self-reported drug or alcohol abuse that, in the opinion of the investigator, would interfere with the subject's ability to comply with study requirements. 16. Screening creatinine elevation with EGFR \< 60 at time of randomization. 17. Tobacco use in last 12 months 18. Pregnancy 19. Prisoners 20. Unable or unwilling to follow-up 21. Unable to understand English/Spanish
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Bmi greater than 30 are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Vanderbilt University Medical Center
Nashville, Tennessee, 37209, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Custom knee guides put to the test in obese patients
- A pill for obesity? early human trial puts MDR-001 to the test
- Can a weekly shot help people who still struggle with weight after bariatric surgery?
- Do GLP-1 Weight-Loss drugs change how teens eat and feel?
- Can electrical muscle stimulation boost exercise benefits after menopause?
- Can a cold cloth on the neck calm Post-Surgery nausea?